AVH Stock Overview
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for AVH from our risk checks.
AVITA Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.77 |
| 52 Week High | US$6.27 |
| 52 Week Low | US$2.66 |
| Beta | 1.29 |
| 1 Month Change | -41.93% |
| 3 Month Change | -42.05% |
| 1 Year Change | -35.28% |
| 3 Year Change | -47.74% |
| 5 Year Change | -60.43% |
| Change since IPO | -94.87% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About AVITA Medical's (ASX:AVH) Cash Burn Situation
Sep 22
We're Interested To See How AVITA Medical (ASX:AVH) Uses Its Cash Hoard To Grow
Jun 02Here's Why We're Not At All Concerned With AVITA Medical's (ASX:AVH) Cash Burn Situation
Jan 11Companies Like AVITA Medical (ASX:AVH) Are In A Position To Invest In Growth
Feb 07Shareholder Returns
| AVH | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -6.1% | 2.8% | 0.9% |
| 1Y | -35.3% | -8.0% | 5.7% |
Return vs Industry: AVH underperformed the Australian Biotechs industry which returned -8% over the past year.
Return vs Market: AVH underperformed the Australian Market which returned 5.7% over the past year.
Price Volatility
| AVH volatility | |
|---|---|
| AVH Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: AVH's share price has been volatile over the past 3 months.
Volatility Over Time: AVH's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 207 | Jim Corbett | www.avitamedical.com |
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time.
AVITA Medical, Inc. Fundamentals Summary
| AVH fundamental statistics | |
|---|---|
| Market cap | AU$339.81m |
| Earnings (TTM) | -AU$54.38m |
| Revenue (TTM) | AU$77.06m |
4.4x
P/S Ratio-6.2x
P/E RatioIs AVH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVH income statement (TTM) | |
|---|---|
| Revenue | US$50.14m |
| Cost of Revenue | US$7.78m |
| Gross Profit | US$42.36m |
| Other Expenses | US$77.74m |
| Earnings | -US$35.38m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 13, 2024
| Earnings per share (EPS) | -1.37 |
| Gross Margin | 84.48% |
| Net Profit Margin | -70.56% |
| Debt/Equity Ratio | 81.2% |
How did AVH perform over the long term?
See historical performance and comparison